JP2022548145A5 - - Google Patents

Info

Publication number
JP2022548145A5
JP2022548145A5 JP2022517139A JP2022517139A JP2022548145A5 JP 2022548145 A5 JP2022548145 A5 JP 2022548145A5 JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022548145 A5 JP2022548145 A5 JP 2022548145A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutical composition
domain
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517139A
Other languages
English (en)
Japanese (ja)
Other versions
JP7773152B2 (ja
JP2022548145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050851 external-priority patent/WO2021055342A1/en
Publication of JP2022548145A publication Critical patent/JP2022548145A/ja
Publication of JP2022548145A5 publication Critical patent/JP2022548145A5/ja
Priority to JP2025182211A priority Critical patent/JP2026021424A/ja
Application granted granted Critical
Publication of JP7773152B2 publication Critical patent/JP7773152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517139A 2019-09-16 2020-09-15 免疫療法の化合物および方法 Active JP7773152B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182211A JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901,198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182211A Division JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Publications (3)

Publication Number Publication Date
JP2022548145A JP2022548145A (ja) 2022-11-16
JP2022548145A5 true JP2022548145A5 (cg-RX-API-DMAC7.html) 2023-09-21
JP7773152B2 JP7773152B2 (ja) 2025-11-19

Family

ID=74883667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517139A Active JP7773152B2 (ja) 2019-09-16 2020-09-15 免疫療法の化合物および方法
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Country Status (10)

Country Link
US (1) US20220324972A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031565A4 (cg-RX-API-DMAC7.html)
JP (2) JP7773152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220087441A (cg-RX-API-DMAC7.html)
CN (1) CN115023435B (cg-RX-API-DMAC7.html)
AU (1) AU2020350524B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154158A1 (cg-RX-API-DMAC7.html)
IL (1) IL291343A (cg-RX-API-DMAC7.html)
WO (1) WO2021055342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
JP7461620B2 (ja) * 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2022505158A5 (cg-RX-API-DMAC7.html)
US20230279101A1 (en) Vegf/dll4 binding agents and uses thereof
JP7308041B2 (ja) 多重特異性抗原結合分子およびその使用
EP3319994B1 (en) Multispecific antigen-binding molecules and uses thereof
ES2719495T3 (es) Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
JP2026035673A (ja) 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
Groner et al. Therapeutic antibodies
US20030157104A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
US11407841B2 (en) Recombinant bi-functional fusion protein and use thereof
RU2018116565A (ru) Терапевтические соединения и способы
JP2010504755A5 (cg-RX-API-DMAC7.html)
CN104768579A (zh) 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
JP2023544143A5 (cg-RX-API-DMAC7.html)
JP2022534724A5 (cg-RX-API-DMAC7.html)
JP2025516703A5 (cg-RX-API-DMAC7.html)
CN103417965A (zh) 一种含有抗vegf抗体的药物组合物
RU2021113936A (ru) Вовлекающие nk молекулы и способы их применения
KR101927732B1 (ko) ErbB3에 특이적으로 결합하는 항체를 포함하는 항암제 내성 암의 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
US12428495B2 (en) Antibodies against YKL-40 and uses thereof
Guilleminault et al. Monoclonal antibodies: An emerging class of therapeutics in non small cell lung cancer
AU2017210673A1 (en) VEGF/DLL4 binding agents and uses thereof
Kiprijanov Bispecific antibodies and immune therapy targeting
TH1901000369A (th) แอนติ-gprc5d แอนติบอดี, โมเลกุลที่ยึดเหนี่ยวแอนติเจนแบบมีสองความจำเพาะซึ่งยึดเหนี่ยวgprc5d และ cd3 และการใช้สิ่งดังกล่าว
HK1255092A1 (en) Multispecific antigen-binding molecules and uses thereof